生物医药系列产品
数据
资源
版本对比
免费注册
预约演示
免费注册
Lumendi
Receives 510(k) Clearance for Two New Devices
2023-02-16
·
BioSpace
上市批准
Company Achieves New Milestone with Over 4,000 Therapeutic Procedures Completed Across the U.S., Europe and Asia, Using DiLumen™ Endoluminal Interventional Platform WESTPORT, Conn.--(BUSINESS WIRE)-- Connecticut-based medical device innovator Lumendi, LLC today announced that it has received U.S.
Food and Drug Administration (FDA)
510(k) clearance for DiLumen EZ¹, a single-use, disposable endotherapy device for endoscopic mucosal resections (EMR) and difficult colonoscopies. The new, more cost-effective design, based on the long-standing success of the DiLumen EZ-Glide platform, has been modified and streamlined. This press release features multimedia. View the full release here: Lumendi, LLC., All Rights Reserved. ©2023 “The DiLumen EZ¹ device will meaningfully enhance our product portfolio by meeting more procedure specific needs for complex polyp resections which are conducted through EMR. Globally, EMR procedures represent the majority share of the over one million polyp resections conducted, annually,” said Dr. Peter Johann, Chief Executive Officer of
Lumendi, Ltd.
The company also announced that it simultaneously received FDA 510(k) clearance of a second device, the DiLumen C¹, which is designed to facilitate complex polyp resection in the colon and rectum via endoscopic submucosal dissection (ESD). C¹’s design offers a single working channel that accommodates an atraumatic grasper, providing more direct tissue manipulation and traction. Use of the C¹ and grasper helps improve curative removal of precancerous and non-invasive cancerous polyps during ESD. Following several years of feedback from leading clinicians,
Lumendi
believes that inadequate stability, tissue manipulation and traction, combined with ineffective cutting, dissecting and cauterizing, continues to be a major challenge for many therapeutic procedures in the digestive tract. With DiLumen, DiLumen EZ1 and DiLumen C1,
Lumendi
now offers a complete set of devices to perform any kind of complex polypectomy and potential other interventions in the entire colon. ”Since 2017, clinicians in the U.S., EU, the UK and Asia, have completed over 4,000 procedures with the commercially available DiLumen
EZ Glide
. These newest devices, when combined with the increasing market adoption of DiLumen EZ Glide, will accelerate
Lumendi
’s continued vision to shift procedures away from invasive gastrointestinal surgeries, towards endoluminal procedures with lower complication rates, little to no hospital stays and very minimal recovery times,” added Dr. Johann. “In addition, based on our success impacting therapeutic procedures in the colon and using our current technology, we will look to expand our development program into upper GI interventions, which we expect will lead to better patient outcomes.” The DiLumen EZ¹ and C¹ are part of a growing platform of accessories that work in conjunction with endoscopes and gastroscopes used in the large intestine, which assist with navigational access, optical visualization, diagnosis and endotherapeutic treatment. About Lumendi, LLC (
Lumendi
) Headquartered in Westport, Connecticut, Lumendi, LLC, is a wholly owned subsidiary of
Lumendi Ltd.
, a privately held, innovative medical device company based in Maidenhead, UK.
Lumendi
focuses on developing, marketing and distributing surgical tools and devices that provide safe, cost-effective solutions for minimally invasive gastrointestinal interventions. Follow us on YouTube
Lumendi
YouTube Twitter
Lumendi USA
更多内容,
请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
Lumendi Ltd.
US Food & Drug Administration
适应症
-
靶点
-
药物
Recombinant protective antigen vaccines(Pfenex, Inc.)
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
来和芽仔聊天吧
热门报告
特应性皮炎深度解析:药物开发、专利分析与风险评估
智慧芽生物医药
2024年7月全球首批及特殊审评药物报告
智慧芽生物医药
GPRC5D靶点专利调研报告
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务